Grants

Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Lewy Body Dementia and Amyloid-Beta Pathology (U01 - Clinical Trial Required) (RFA-NS-25-010)

Tools

Back to the Top

Sponsor

National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award

Direct Costs cannot exceed $6,700,000 per year. The maximum project period is 7 years. NIH intends to fund one award contingent upon NIH appropriations.

Due Date

LOI due December 24, 2024. Application due January 24, 2025.

View Grant